Drug Trial Radar · NCT02115204
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Last checked: Nov 19, 2026Latest source record: Oct 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,011
Actual
Start
Jun 2000
Primary completion
Aug 2005
Study completion Aug 2010
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AGO Germany
- First posted
- Apr 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and "Arbeitsgemeinschaft Gynäkologische Onkologie" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).
Conditions
- Breast Cancer
Interventions
EpirubicinDrug
CyclophosphamideDrug
DocetaxelDrug
MethotrexateDrug
5-fluorouracilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of event-free survivalTime frame: 60 months after end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ev. Hospital Bethesda
Mönchengladbach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.